CytomX Therapeutics Inc (CTMX) Holdings Lifted by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. raised its holdings in shares of CytomX Therapeutics Inc (NASDAQ:CTMX) by 12.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 198,366 shares of the biotechnology company’s stock after purchasing an additional 21,864 shares during the period. Schwab Charles Investment Management Inc. owned 0.51% of CytomX Therapeutics worth $5,644,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in CytomX Therapeutics by 32.9% during the 4th quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock valued at $15,096,000 after purchasing an additional 177,200 shares during the last quarter. AMP Capital Investors Ltd raised its position in CytomX Therapeutics by 64.7% during the 4th quarter. AMP Capital Investors Ltd now owns 66,621 shares of the biotechnology company’s stock valued at $1,406,000 after purchasing an additional 26,183 shares during the last quarter. Redmile Group LLC raised its position in CytomX Therapeutics by 9.5% during the 4th quarter. Redmile Group LLC now owns 418,680 shares of the biotechnology company’s stock valued at $8,838,000 after purchasing an additional 36,409 shares during the last quarter. Two Sigma Investments LP raised its position in CytomX Therapeutics by 12.0% during the 4th quarter. Two Sigma Investments LP now owns 153,340 shares of the biotechnology company’s stock valued at $3,237,000 after purchasing an additional 16,479 shares during the last quarter. Finally, Iguana Healthcare Management LLC raised its position in CytomX Therapeutics by 7.1% during the 4th quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biotechnology company’s stock valued at $1,583,000 after purchasing an additional 5,000 shares during the last quarter. 76.24% of the stock is owned by institutional investors and hedge funds.

Shares of CytomX Therapeutics opened at $24.58 on Friday, Marketbeat Ratings reports. CytomX Therapeutics Inc has a 52-week low of $13.09 and a 52-week high of $35.00.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.17). CytomX Therapeutics had a negative return on equity of 92.68% and a negative net margin of 67.88%. The firm had revenue of $14.18 million during the quarter, compared to the consensus estimate of $19.77 million. equities research analysts predict that CytomX Therapeutics Inc will post -1.66 EPS for the current fiscal year.

A number of research analysts have commented on CTMX shares. ValuEngine raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. BidaskClub lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 18th. Bank of America upped their price target on CytomX Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 8th. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Tuesday, May 8th. Finally, Jefferies Financial Group increased their target price on CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $38.38.

In other news, CFO Debanjan Ray sold 3,000 shares of the stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $25.93, for a total value of $77,790.00. Following the completion of the transaction, the chief financial officer now owns 5,928 shares of the company’s stock, valued at approximately $153,713.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frederick W. Gluck sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 26th. The stock was sold at an average price of $31.93, for a total value of $159,650.00. The disclosure for this sale can be found here. Insiders sold a total of 33,578 shares of company stock valued at $921,156 in the last three months. Corporate insiders own 8.50% of the company’s stock.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply